Pharmacologic management of mesenteric occlusive disease

William H. Frishman, Sofia Novak, Lawrence J. Brandt, Adam Spiegel, Andrew Gutwein, Maureen Kohi, Grigory Rozenblit

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Mesenteric vascular disease has been diagnosed increasingly over the past 25 years. This rise in incidence has been attributed to the advanced mean age of the population, an increasing number of critically ill patients and a greater clinical recognition of the condition. Although surgical revascularization and resection has long been the standard of treatment, medical management can also play an important adjunctive role. Early diagnosis before irreversible bowel damage, which may occur within 6-8 hours after the insult, is necessary to improve survival and reduce morbidity. Even in the presence of irreversible bowel ischemia, perioperative medical treatment may reduce disease progression, enabling more limited bowel resection. This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
JournalCardiology in Review
Volume16
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Vascular Diseases
Critical Illness
Intestines
Disease Progression
Early Diagnosis
Therapeutics
Ischemia
Morbidity
Survival
Incidence
Population

Keywords

  • Acute/chronic mesenteric ischemia
  • Colon ischemia
  • Mesenteric vascular disease
  • Mesenteric venous thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Frishman, W. H., Novak, S., Brandt, L. J., Spiegel, A., Gutwein, A., Kohi, M., & Rozenblit, G. (2008). Pharmacologic management of mesenteric occlusive disease. Cardiology in Review, 16(2), 59-68. https://doi.org/10.1097/CRD.0b013e31815a6600

Pharmacologic management of mesenteric occlusive disease. / Frishman, William H.; Novak, Sofia; Brandt, Lawrence J.; Spiegel, Adam; Gutwein, Andrew; Kohi, Maureen; Rozenblit, Grigory.

In: Cardiology in Review, Vol. 16, No. 2, 03.2008, p. 59-68.

Research output: Contribution to journalArticle

Frishman, WH, Novak, S, Brandt, LJ, Spiegel, A, Gutwein, A, Kohi, M & Rozenblit, G 2008, 'Pharmacologic management of mesenteric occlusive disease', Cardiology in Review, vol. 16, no. 2, pp. 59-68. https://doi.org/10.1097/CRD.0b013e31815a6600
Frishman, William H. ; Novak, Sofia ; Brandt, Lawrence J. ; Spiegel, Adam ; Gutwein, Andrew ; Kohi, Maureen ; Rozenblit, Grigory. / Pharmacologic management of mesenteric occlusive disease. In: Cardiology in Review. 2008 ; Vol. 16, No. 2. pp. 59-68.
@article{b0e84377ad9d4c53a6eab18e91fb029f,
title = "Pharmacologic management of mesenteric occlusive disease",
abstract = "Mesenteric vascular disease has been diagnosed increasingly over the past 25 years. This rise in incidence has been attributed to the advanced mean age of the population, an increasing number of critically ill patients and a greater clinical recognition of the condition. Although surgical revascularization and resection has long been the standard of treatment, medical management can also play an important adjunctive role. Early diagnosis before irreversible bowel damage, which may occur within 6-8 hours after the insult, is necessary to improve survival and reduce morbidity. Even in the presence of irreversible bowel ischemia, perioperative medical treatment may reduce disease progression, enabling more limited bowel resection. This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory.",
keywords = "Acute/chronic mesenteric ischemia, Colon ischemia, Mesenteric vascular disease, Mesenteric venous thrombosis",
author = "Frishman, {William H.} and Sofia Novak and Brandt, {Lawrence J.} and Adam Spiegel and Andrew Gutwein and Maureen Kohi and Grigory Rozenblit",
year = "2008",
month = "3",
doi = "10.1097/CRD.0b013e31815a6600",
language = "English (US)",
volume = "16",
pages = "59--68",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Pharmacologic management of mesenteric occlusive disease

AU - Frishman, William H.

AU - Novak, Sofia

AU - Brandt, Lawrence J.

AU - Spiegel, Adam

AU - Gutwein, Andrew

AU - Kohi, Maureen

AU - Rozenblit, Grigory

PY - 2008/3

Y1 - 2008/3

N2 - Mesenteric vascular disease has been diagnosed increasingly over the past 25 years. This rise in incidence has been attributed to the advanced mean age of the population, an increasing number of critically ill patients and a greater clinical recognition of the condition. Although surgical revascularization and resection has long been the standard of treatment, medical management can also play an important adjunctive role. Early diagnosis before irreversible bowel damage, which may occur within 6-8 hours after the insult, is necessary to improve survival and reduce morbidity. Even in the presence of irreversible bowel ischemia, perioperative medical treatment may reduce disease progression, enabling more limited bowel resection. This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory.

AB - Mesenteric vascular disease has been diagnosed increasingly over the past 25 years. This rise in incidence has been attributed to the advanced mean age of the population, an increasing number of critically ill patients and a greater clinical recognition of the condition. Although surgical revascularization and resection has long been the standard of treatment, medical management can also play an important adjunctive role. Early diagnosis before irreversible bowel damage, which may occur within 6-8 hours after the insult, is necessary to improve survival and reduce morbidity. Even in the presence of irreversible bowel ischemia, perioperative medical treatment may reduce disease progression, enabling more limited bowel resection. This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory.

KW - Acute/chronic mesenteric ischemia

KW - Colon ischemia

KW - Mesenteric vascular disease

KW - Mesenteric venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=39449115815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449115815&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e31815a6600

DO - 10.1097/CRD.0b013e31815a6600

M3 - Article

VL - 16

SP - 59

EP - 68

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 2

ER -